act-1014-6470
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 16, 2019 (NCT04183686)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C5a anaphylatoxin chemotactic receptorANTAGONIST
C5AR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05123820 | Phase 1 | Nov 5, 2021 | Idorsia Pharmaceuticals Ltd. |
| NCT04899219 | Phase 1 | Jun 16, 2021 | Idorsia Pharmaceuticals Ltd. |
| NCT04608513 | Phase 1 | Oct 29, 2020 | Idorsia Pharmaceuticals Ltd. |
| NCT04183686 | Phase 1 | Dec 16, 2019 | Idorsia Pharmaceuticals Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Idorsia Pharmaceuticals Ltd. | For profit | 4 | 4 | 1 | 2019 |
1 organizations
Page 1 / 1